Brielle Benyon

2 months ago | targetedonc.com | Brielle Benyon

AFTER 8.4 years of follow-up, ado-trastuzumab emtansine (T-DM1; Kadcyla) led to improved overall survival (OS) and invasive disease–free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial (NCT01772472) that were presented at the 2024 San Antonio Breast Cancer Symposium in Texas.

Dec 24, 2024 | onclive.com | Brielle Benyon

For Edward S. Kim, MD, much of his life revolved around rewriting the rules both professionally and personally. Those in the oncology space might know him as the man working tirelessly to improve clinical trial access or leading several practice-changing research studies, including the BATTLE trial’s (NCT00409968) landmark research that laid the groundwork for the use of biomarkers to personalize lung cancer care.

Nov 25, 2024 | oncnursingnews.com | Brielle Benyon

Genetic testing results can have numerous implications in cancer care—from targeted treatment regimens to the need for family members to get tested. Oncology nurses are in a prime position to help guide patients through the process, according to Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC. Sabo-Wagner is the vice president of Clinical Innovation for American Oncology Network.

Nov 20, 2024 | oncnursingnews.com | Brielle Benyon

Tapering treatment with opioids for cancer-related pain can be a challenging process. However, when there is suspected opioid misuse, clinicians should consider faster tapering combined with non-opioid treatments to prevent harm to the patient or others, explained Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAANP.

Nov 18, 2024 | oncnursingnews.com | Brielle Benyon

The use of bispecific antibodies have brought landmark change for the treatment of relapsed/refractory multiple myeloma, and tend to be well-tolerated, explained Carrie Lechtenberger, APRN, FNP-C, CCM, OCN, CBCN. “[Bispecific antibodies] are exciting. What they do is great, and I think patients overall have pretty tolerable, if any, side effects,” Lechtenberger, a family nurse practitioner at Levine Cancer Institute, Atrium Health, said.